Prestige Biopharma, a Singapore-based biopharmaceutical company specialising in antibody therapeutics, announced on Tuesday that it has signed an exclusive licence and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina.

This agreement covers the commercialisation of Tuznue (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.

Tuznue is a biosimilar to Herceptin (trastuzumab), approved for the treatment of breast cancer and metastatic gastric cancer.

Under the agreement, Biosidus receives exclusive rights to market and distribute Tuznue in Argentina, Mexico, Bolivia, and Paraguay, using its extensive commercial network and expertise in biosimilar adoption. Prestige Biopharma will be responsible for production and supply of the drug substance through its EU-GMP-certified, high-tech facility equipped with advanced single-use technology. Biosidus will produce the drug product at its facility in Buenos Aires, from which it will supply the product to the local market and export it to Mexico, Paraguay and Bolivia.